| Previous close | 32.87 |
| Open | 32.87 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 220.00 |
| Expiry date | 2025-01-17 |
| Day's range | 32.87 - 32.87 |
| Contract range | N/A |
| Volume | |
| Open interest | 235 |
- GuruFocus.com
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts
Despite Revenue Decline, Non-GAAP EPS Growth and Strategic Initiatives Show Promise
ReutersBiogen cost cuts drive profit beat, Alzheimer's drug sales jump
(Reuters) -Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell. The launch has led to profound changes in how doctors treat Alzheimer's patients, and challenges include the "amount of effort it takes to actually be able to initiate even the first patient", CEO Christopher Viehbacher said in an interview. The number of patients on Leqembi have increased nearly 2.5 times from roughly 2,000 patients at the end of 2023, Biogen said.
Investor's Business DailyTwo Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and could help Biogen stock reverse a recent downtrend.
